For many companies, relocating pharmaceutical production capacities back to Europe is becoming a key strategic success factor. Saltigo, LANXESS`s exclusive synthesis subsidiary, helps pharmaceutical manufacturers strengthen their supply chains, meet regulatory requirements, and achieve sustainability goals in production. At CPHI Frankfurt 2025 (October 28-30 at the Messe Frankfurt), Saltigo will present solutions that will enable pharmaceutical companies to strengthen their supply chains through targeted reshoring, minimize regulatory risks, and produce more sustainably.
Industry in transition: Return to Regional Value Chains
The European pharmaceutical industry is facing growing dependencies on Asia. China and India dominate the market for active pharmaceutical ingredients (API`s) and many of their precursors. This market concentration poses significant supply risks, particularly in the event of geopolitical tensions, export restrictions, or disruptions to global supply chains. To increase supply and production security, the European Union has launched several initiatives in recent years. These include the Critical Medicines Alliance, established in 2024, and the Strategic Report on Medicines Supply, released in February 2025. These initiatives aim to bolster the European production of critical medicines and their precursors, securing Europe`s long-term strategic independence in the pharmaceutical sector.
New platforms, such as the European Shortage Monitoring Platform (ESMP), and guidelines for preventing bottlenecks enable the EU to establish more resilient supply chain structures. For the industry, diversifying manufacturing locations is becoming a strategic priority, especially for regulatory starting materials (RSM`s) and complex intermediates, which often cause bottlenecks in the value chain.
Saltigo as a pioneer for resilient supply chains
Saltigo positions itself as a reliable partner for customized chemical syntheses and scalable production solutions in Europe. With sites in Leverkusen and Dormagen, Saltigo offers manufacturing in multipurpose facilities that combine the highest regulatory standards, short delivery routes, strict IP protection, and flexible capacities. Global raw material sourcing within the Group complements this setup of Western supply chains, ensuring more stable processes, lower costs, and shorter time-to-market.
Speed and scalability are decisive advantages. Saltigo can assess new projects technically within a few days and provide initial price estimates. This alleviates short-term bottlenecks in API production.
Saltigo`s technological spectrum includes advanced processes such as olefin metathesis, high-pressure hydrogenation, fluorine and phosgene chemistry, and continuous processes (flow chemistry). Close integration of process development, piloting, and commercial manufacturing enables efficient project transfer from laboratory to large-scale production.
Sustainability as a distinguishing feature
In addition to technological expertise, Saltigo is committed to transparency in its product carbon footprint (PCF). PCF data is available for many products, and the company develops net-zero routes for CO₂-neutral production upon request. In this way, Saltigo contributes to the climate goals of the pharmaceutical industry and strengthens the competitiveness of European supply chains.
Meeting place CPHI Frankfurt
At CPHI 2025, Saltigo invites employees of pharmaceutical companies and CDMO to learn about the latest technologies and services and discuss individual projects. “We support our pharmaceutical industry partners when their plants reach capacity limits or when they want to focus on high-value API synthesis,” emphasizes Christoph Schaffrath, Saltigo`s Head of Marketing and Sales.
Interested visitors can find Saltigo at CPHI Frankfurt 2025 in Hall 4.1, Booth K27. Appointments with experts can be arranged in advance or during the trade fair.
Further information about the trade fair can be found at https://lanxess.com/en/company/corporate-structure/subsidiaries/saltigo/cphi.
